FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
9 letters match. Newest first.
-
DrugsTelos Trading Limited dba Alwinshop
FDA warns UK online seller Alwinshop that its "Prostatitis Remission Cream" is an unapproved, misbranded drug with false FDA endorsement claims.
High risk -
DrugsAltru Telehealth, LLC dba Altru Telehealth
FDA warns Altru Telehealth that its website falsely claimed compounded semaglutide/tirzepatide and compounding pharmacies were FDA-approved.
Low -
DrugsThrivelab Co. dba Thrivelab
FDA warned telehealth seller Thrivelab that its website misbrands compounded semaglutide with false claims suggesting FDA approval.
Medium -
DrugsMomentum Health 360 dba Momentum Health
FDA warned Momentum Health over false claims for compounded semaglutide, tirzepatide, and liraglutide.
Low -
DrugsMedica Weight Loss
FDA warns telehealth seller Medica Weight Loss that its compounded semaglutide and tirzepatide web claims are false and misbrand the drugs.
Medium -
DrugsFITISH
FDA warned FITISH over misleading website claims for compounded semaglutide and tirzepatide, including labels suggesting it is the compounder.
Low -
DrugsKin Meds
FDA warned Kin Meds over false claims for compounded semaglutide and tirzepatide, including implying it is the compounder and that products are approved.
Low -
Drugs24HrDoc, Inc. dba 24HrDoc
FDA says 24HrDoc's website misbrands compounded semaglutide and tirzepatide with false claims that it compounds them and that they match Ozempic, Wegovy, Mounjaro, Zepbound.
Medium -
DrugsGenesis Health International Inc. dba Genesis
FDA warns Genesis over misleading website claims for compounded semaglutide and tirzepatide.
Low